# ASAIO JOURNAL-VOLUME 39

## Subject Index

**Editor's Note:** This index encompasses only the material presented in this issue of ASAIO JOURNAL Volume 39, Numbers 1, 2, and 4. Please consult the July–September issue (Vol. 39, No. 3) for an index of the contents of that body of work.


**A**

Activated clotting time
  with heparinase, in management of pediatric patients on cardiopulmonary bypass, 942
  in neonatal extracorporeal membrane oxygenation patients, predictive performance of three methods of measurement of, 39
Aortic leaflets, porcine, arrangement of, clinical xenograft failure and, 918
Arterial grafts, bovine, epoxy ether fixed, evaluation for mutagenic potential, 106
Arteriovenous fistulae, wearable system for continuous monitoring of, 137
Autoimmune disease, usefulness of selective macromolecule removal plasmapheresis systems for, 868
Autonomic function, in normotensive and hypertension-prone dialysis patients, 946

**B**

Blood pumps, pneumatic membrane, electric model with time varying resistance for, 56
Body weight, adequacy of hemodialysis and, 933
Bulk hydroxyl percentage, relationship between human serum- or plasma-material interaction and, 910

**C**

Carbon dioxide, intracorporeal removal of, to reduce airway pressure in acute respiratory failure, 97
Cardiac transplantation, bridging to, life quality and, 145
Cardiopulmonary bypass
  activated clotting time tests with heparinase in management of pediatric patients on, 942
  hypothermic, effects of pump flow rate on oxygen use during, 126
  left, coagulation patterns with phospholipid *versus* heparin surface coating, 43
  pulsatile cardiopulmonary bypass system preventing negative pressure at membrane oxygenator, 936
Catecholamines, in normotensive and hypertension-prone dialysis patients, 946
Catheters, Moncrief-Popovich, 62
Centrifugal pump, clinical application of percutaneous left ventricular support with, 153
Children, activated clotting time tests with heparinase in management of pediatric patients on cardiopulmonary bypass, 942
Chronic intermittent peritoneal dialysis, 962
Coagulation, patterns in bovine left heart bypass with phospholipid *versus* heparin surface coating, 43
Color Doppler echocardiography, assessment of effects of intraaortic balloon pumping on portal venous flow by, 103
Computer models, performance optimization of left ventricular assistance and, 29
Continuous ambulatory peritoneal dialysis
  with high flux membrane, 904
  hyperlipidemia and, 87
Continuous dialysis, wearable artificial kidneys for, 19
Counterpulsation, muscle and pneumatic-powdered left ventricular assist devices and, 825
Cyclosporine, intermediate-term outcome of renal retransplants and, 47

**D**

Diabetes mellitus, dialysis in, relationship between glycemic control and morbidity and mortality and, 880
Dialysis. *See also* Hemodialysis
  access for, spun elastomeric graft for, 114
  building acute dialysis machine in Korea, 957
  continuous, wearable artificial kidneys for, 19
  cost and bother of intradialytic parenteral nutrition and, 864
  in diabetes mellitus, relationship between glycemic control and morbidity and mortality and, 880
  early, 828
  long slow, survival and, 819
  national surveillance of diseases associated with in United States during 1991, 966
  peritoneal. *See* Peritoneal dialysis
  plasma catecholamines, autonomic, and left ventricular function in normotensive and hypertension-prone patients on, 946

**E**

Elastomeric graft, spun, for dialysis access, 114
Endothelial cell seeding, perianastomotic findings in canine grafts at 3 months, 132
Endotoxin, clearance through whole body rinse out in relation histologic integrity, in rat, 141
Erythrocytosis, after renal transplantation, 51
Erythropoietin, discovery of, 89
Extracorporeal Life Support Organization, 976
Extracorporeal membrane oxygenation, in neonates
  predictive performance of three methods of activated clotting measurement in, 39
  term, cost-benefit analysis of, 873

**H**

Heart, total artificial. *See* Total artificial heart
Heart valves
  mechanical, *in vitro* strain measurement in pulse simulator, 929
  porcine, aortic leaflet arrangement of, clinical xenograft failure and, 918
Hemodialysis
  adequacy of, body weight and, 933
  national surveillance of diseases associated with in United States during 1990, 71

# ASAIO JOURNAL-VOLUME 39

## Subject Index

**Editor's Note:** This index encompasses only the material presented in this issue of ASAIO JOURNAL Volume 39, Numbers 1, 2, and 4. Please consult the July–September issue (Vol. 39, No. 3) for an index of the contents of that body of work.


**A**

Activated clotting time
  with heparinase, in management of pediatric patients on cardiopulmonary bypass, 942
  in neonatal extracorporeal membrane oxygenation patients, predictive performance of three methods of measurement of, 39
Aortic leaflets, porcine, arrangement of, clinical xenograft failure and, 918
Arterial grafts, bovine, epoxy ether fixed, evaluation for mutagenic potential, 106
Arteriovenous fistulae, wearable system for continuous monitoring of, 137
Autoimmune disease, usefulness of selective macromolecule removal plasmapheresis systems for, 868
Autonomic function, in normotensive and hypertension-prone dialysis patients, 946

**B**

Blood pumps, pneumatic membrane, electric model with time varying resistance for, 56
Body weight, adequacy of hemodialysis and, 933
Bulk hydroxyl percentage, relationship between human serum- or plasma-material interaction and, 910

**C**

Carbon dioxide, intracorporeal removal of, to reduce airway pressure in acute respiratory failure, 97
Cardiac transplantation, bridging to, life quality and, 145
Cardiopulmonary bypass
  activated clotting time tests with heparinase in management of pediatric patients on, 942
  hypothermic, effects of pump flow rate on oxygen use during, 126
  left, coagulation patterns with phospholipid *versus* heparin surface coating, 43
  pulsatile cardiopulmonary bypass system preventing negative pressure at membrane oxygenator, 936
Catecholamines, in normotensive and hypertension-prone dialysis patients, 946
Catheters, Moncrief-Popovich, 62
Centrifugal pump, clinical application of percutaneous left ventricular support with, 153
Children, activated clotting time tests with heparinase in management of pediatric patients on cardiopulmonary bypass, 942
Chronic intermittent peritoneal dialysis, 962
Coagulation, patterns in bovine left heart bypass with phospholipid *versus* heparin surface coating, 43
Color Doppler echocardiography, assessment of effects of intraaortic balloon pumping on portal venous flow by, 103
Computer models, performance optimization of left ventricular assistance and, 29
Continuous ambulatory peritoneal dialysis
  with high flux membrane, 904
  hyperlipidemia and, 87
Continuous dialysis, wearable artificial kidneys for, 19
Counterpulsation, muscle and pneumatic-powdered left ventricular assist devices and, 825
Cyclosporine, intermediate-term outcome of renal retransplants and, 47

**D**

Diabetes mellitus, dialysis in, relationship between glycemic control and morbidity and mortality and, 880
Dialysis. *See also* Hemodialysis
  access for, spun elastomeric graft for, 114
  building acute dialysis machine in Korea, 957
  continuous, wearable artificial kidneys for, 19
  cost and bother of intradialytic parenteral nutrition and, 864
  in diabetes mellitus, relationship between glycemic control and morbidity and mortality and, 880
  early, 828
  long slow, survival and, 819
  national surveillance of diseases associated with in United States during 1991, 966
  peritoneal. *See* Peritoneal dialysis
  plasma catecholamines, autonomic, and left ventricular function in normotensive and hypertension-prone patients on, 946

**E**

Elastomeric graft, spun, for dialysis access, 114
Endothelial cell seeding, perianastomotic findings in canine grafts at 3 months, 132
Endotoxin, clearance through whole body rinse out in relation histologic integrity, in rat, 141
Erythrocytosis, after renal transplantation, 51
Erythropoietin, discovery of, 89
Extracorporeal Life Support Organization, 976
Extracorporeal membrane oxygenation, in neonates
  predictive performance of three methods of activated clotting measurement in, 39
  term, cost-benefit analysis of, 873

**H**

Heart, total artificial. *See* Total artificial heart
Heart valves
  mechanical, *in vitro* strain measurement in pulse simulator, 929
  porcine, aortic leaflet arrangement of, clinical xenograft failure and, 918
Hemodialysis
  adequacy of, body weight and, 933
  national surveillance of diseases associated with in United States during 1990, 71

Hemofiltration, high volume, veno-venous bypass and, during orthoptic liver transplantation, 954
Heparinase, activated clotting time tests with, in management of pediatric patients on cardiopulmonary bypass, 942
Heparin surface coating, coagulation patterns in bovine left heart bypass with, 43
Hypercapnia, permissive, to reduce airway pressure in acute respiratory failure, 97
Hyperlipidemia
in continuous ambulatory peritoneal dialysis patients, 87
usefulness of selective macromolecule removal plasmapheresis systes for, 868

I

Insulin, release from bioartificial pancreas using mesh reinforced polyvinyl alcohol hydrogel tube, 93
Intraaortic balloon pumping, effects on portal venous flow, 103
Islet organoid, histologic appearance of, 893

K

Kidneys. *See also* renal transplantation
artificial, wearable, for continuous dialysis, 19

L

Larynx, electronic control of pathologic tone disturbances in, 24
Left ventricular assist devices
mechanical, early, 834
muscle and pneumatic-powered, 825
percutaneous, clinical application with centrifugal pump, 153
performance optimization of, 29
Left ventricular function, in normotensive and hypertension-prone dialysis patients, 946
Liquid-liquid oxygenators, 923
Liver, bioartificial, mass transfer in hollow fiber device used as, 886
Liver transplantation, orthoptic, combined veno-venous bypass and high volume hemofiltration during, 954

M

Moncrief-Popovich catheter, 62
Mutation, evaluation of bovine, epoxy ether fixed arterial grafts for mutagenic potential, 106

N

Neonates, extracorporeal membrane oxygenation in
cost-benefit analysis of, 873
predictive performance of three methods of activated clotting measurement in, 39

O

Oxygen, use during moderate hypothermic cardiopulmonary bypass, effects of pump flow rate on, 126
Oxygenators
liquid-liquid, 923
pulsatile cardiopulmonary bypass system preventing negative pressure at, 936

P

Pancreas, bioartificial, using mesh reinforced polyvinyl alcohol hydrogel tube, insulin release from, 93
Parenteral nutrition, intradialytic, cost and bother of, 864
Peritoneal dialysis
chronic intermittent, 962
continuous ambulatory, with high flux membrane, 904
hyperlipidemia in continuous ambulatory peritoneal dialysis patients, 87
Moncrief-Popovich catheter for, 62
Peritoneal transfer, during maximal hyperosmotic ultrafiltration in rat, 66
Phospholipid, coagulation patterns in bovine left heart bypass with, 43
Plasma, interaction with material, polymer bulk hydrogel and surface oxygen content and, 910
Plasmapheresis, usefulness for autoimmune disease and hyperlipidemia, 868
Pneumatic membrane blood pumps, electric model with time varying resistance for, 56
Portal venous flow, effects of intraaortic balloon pumping on, 103
Pumps
centrifugal, clinical application of percutaneous left ventricular support with, 153
effects of pump flow rate on oxygen use during moderate hypothermic cardiopulmonary bypass, 126

Q

Quality of life, bridging to cardiac transplantation and, 145

R

Recombinant erythropoietin
effect of marketplace on socialized patient care and, 85
usage in United States, 11
Renal transplantation
erythrocytosis after, 51
intermediate-term outcome of retransplants in cyclosporine era, 47
Respiratory failure, acute, intracorporeal $CO_2$ removal and permissive hypercapnea to reduce airway pressure in, 97
Right ventricular assistance, with thoracotomy, feasibility and efficacy of, 120

S

Serum, interaction with material, polymer bulk hydrogel and surface oxygen content and, 910
Surface oxygen content, relationship between human serum- or plasma-material interaction and, 910

T

Thoracotomy, feasibility and efficacy of right ventricular assistance without, 120
Total artificial heart
clinical use of, state of the art in 1993, 840

electrohydraulic, adaptive full-ejection point detection for automatic control of, 899
future development of, 856

U

Ultrafiltration, peritoneal transfer during maximal hyperosmotic ultrafiltration in rat, 66

V

Veno-venous bypass, high volume hemofiltration and, during orthoptic liver transplantation, 954
Ventricular assist devices
clinical use of, state of the art in 1993, 840
future development of, 856
left. *See* Left ventricular assist devices

# Author Index


A

Alter, Miriam J., 39:71, 39:966
Araki, Kenji, 39:120
Arioka, Ichiro, 39:936
Armitage, John M., 39:145
Asano, Haruhiko, 39:103
Aung, Tun, 39:93
Avasthi, Pratap S., 39:880

B

Baclig, Lita, 39:106
Barnea, Ofer, 39:29
Bartlett, Robert H., 39:873, 39:976
Bellomo, Rinaldo, 39:954
Besarab, Anatole, 39:11, 39:85
Bidani, Akhil, 39:97
Bland, Lee A., 39:71, 39:966
Broadrick, Linda Jo, 39:62
Broniatowski, Michael, 39:24
Bronsther, Oscar, 39:954
Burczak, Krystyna, 39:93
Burghen, George A., 39:893

C

Capretta, Carla, 39:145
Chapman, Robin, 39:873
Charra, Bernard, 39:819
Chen, Tzen W., 39:66
Cochran, Richard P., 39:918
Cody, Ronald P., 39:933
Cox, Charles S., Jr., 39:97

D

Daniels, Ethelyn, 39:954
Daskalakis, Paula, 39:47, 39:51
David, Tirone E., 39:918
Delosh, Thomas, 39:976
Demetriou, Achilles A., 39:886
Dew, Mary Amanda, 39:145
Diang, Liang-Kuang, 39:946
Drasler, William J., 39:114
Dubin, Stephen E., 39:29
Dutcher, Robert G., 39:114

E

Egami, Jun, 39:132
Eisenberg, Brian, 39:880
Erslev, Allan J., 39:85, 39:89

F

Farley, Joanne, 39:106
Favero, Martin S., 39:71, 39:966
Friedman, Eli A., 39:47, 39:51
Fujisato, Toshiya, 39:93
Fukumura, Fumio, 39:126
Fukunaga, Shintaro, 39:923
Fung, John J., 39:954

G

Gamboa, Susan, 39:904
George, Stephanie A., 39:114
Giorgio, Todd D., 39:886
Goh, K. S., 39:929
Grande, Kathryn J., 39:918
Graves, Donna F., 39:97
Griffith, Bartley P., 39:145
Grzegorzewska, Alicja, 39:66
Gu, Yuanjun, 39:93
Guida, Sarah, 39:106
Guidubaldi, John M., 39:910

H

Hall, C. William, 39:9
Harris, Clyde, 39:954
Harris, Ronna C., 39:145
Hatane, Toshihiko, 39:120
He, Zheng Zhi, 39:62
Herrod, Henry G., 39:893
Higashino, Hideaki, 39:141
Hisahara, Manabu, 39:126
Hong, Joon H., 39:47, 39:51

I

Idezuki, Yasuo, 39:132
Ikada, Yoshito, 39:93
Imawaki, Setsuro, 39:936
Inoue, Itaru, 39:137
Inoue, Kazutomo, 39:93

J

Jaron, Dov, 39:29
Jenson, Mark L., 39:114
Jiang, Hann-Kuang, 39:943
Jin, Zonghao, 39:56
Joyner, Royce, 39:893

K

Kajihara, Hiroki, 39:923
Kaneko, Mitsunori, 39:153
Kang, Yoogoo, 39:954
Kantrowitz, Adrian, 39:834
Kaplan, Andre, 39:868
Kato, Tatsunori, 39:137
Kawachi, Yoshito, 39:126
Kenmoku, Kyoichi, 39:103
Keshaviah, Prakash, 39:904
Khanna, Ramesh, 39:904
Khanwilkar, Pratap S., 39:899
Kim, Hee Chan, 39:899
Kimura, Sousuke, 39:103
Kitzhaber, John A., 39:1
Kobayashi, Tohru, 39:153
Koga, Yasunori, 39:120
Kogire, Masafumi, 39:93
Kolff, William J., 39:825
Komoda, Takeshi, 39:936
Koo, Anna P., 39:868
Kormos, Robert L., 39:145
Kreismer, Pamela J., 39:39
Kriesmer, Pamela, 39:942
Kunzelman, Karyn S., 39:918
Kuo, Chao Y., 39:893
Kurisu, Kazuhiro, 39:126

L

Lai, Ween-Yuang, 39:946
Lal, Sunder M., 39:87
Lee, K. H., 39:929
Leskosek, B., 39:43
Lin, Yuh-Feng, 39:946
Lohre, Jeffrey M., 39:106
Long, James W., Jr., 39:899
Lu, Kuo-Cheng, 39:946

M

Maeda, Kenji, 39:137
Maeda, Mitsuyo, 39:141
Maeta, Hajime, 39:936
Maetani, Shunzo, 39:93
Malchesky, Paul S., 39:868, 39:910
Markell, Mariana S., 39:47, 39:51
Matsuda, Hikaru, 39:153
Matsuo, Keiichiro, 39:120
Matsuura, Yuichiro, 39:923
McCrea, Jacqueline B., 39:11
Miles, Anne Marie, 39:47, 39:51
Mitsuo, Manabu, 39:93
Moncrief, Jack W., 39:62
Moore, Harold L., 39:66, 39:904
Moore, Thomas W., 39:29
Mortimer, Bradley J., 39:840
Moscioni, Albert D., 39:886
Moyer, Linda A., 39:71, 39:966
Murata, Glen H., 39:880
Myracle, Angela D., 39:893

N

Nakai, Shigeru, 39:137
Nakano, Susumu, 39:153
Nakashima, Atsuhiro, 39:126
Nasu, Norio, 39:936
Nikolova, Irina, 39:141
Niranjan, S. C., 39:97
Nolph, Karl D., 39:66, 39:904
Nugent, A. H., 39:929

O

Olah, A., 39:43
Olsen, Don B., 39:840, 39:899
Omoto, Ryozo, 39:103
Onitsuka, Toshio, 39:120
Oreopoulos, Dimitrios G., 39:962

P

Payne, Nathaniel R., 39:39, 39:942
Platt, Karen L., 39:29
Poirier, Victor L., 39:856
Popovich, Robert P., 39:62
Possis, Zinon C., 39:114
Pristas, John M., 39:145
Prowant, Barbara, 39:904

Q

Qin, Jianan, 39:56
Quijano, R. C., 39:106

R

Roberts, Martin, 39:19
Roloff, Dietrich W., 39:873
Roth, Loren H., 39:145
Rowles, John R., 39:840
Rozga, Jacek, 39:886

S

Sakurada, Yutaka, 39:868
Sarkar, Salil, 39:51
Sato, Osamu, 39:132
Satoh, Hisashi, 39:153
Sawada, Koji, 39:910
Schreiner, George E., 39:828
Schumacher, Robert E., 39:873
Seay, Russell E., 39:39
Sherman, Richard A., 39:933
Shibata, Koichiro, 39:120
Shieh, Shang-Der, 39:946
Shimazaki, Yasuhisa, 39:153
Shimoyama, Takashi, 39:910
Shindo, Shunya, 39:132
Shinohara, Shigeo, 39:93
Shinozuka, Nozomi, 39:103
Shinzato, Takahiro, 39:137
Shiraishi, Yasushi, 39:936
Shum, Andrew Y-C, 39:946
Siami, Ghodrat A., 39:868
Simmons, Everett E., 39:62
Siraishi, Kiminori, 39:126
Snedecor, Sandy, 39:873
Solanchick, Joan C., 39:933
Sommer, Bruce G., 39:47, 39:51
Stenoien, Mark D., 39:114
Stolar, Charles J. H., 39:976
Sueda, Taijiro, 39:923
Sueoka, Akinori, 39:910
Sukigara, Minoru, 39:103
Sumrani, Nabil B., 39:47, 39:51
Suzuki, Aritomo, 39:141

T

Tada, Yusuke, 39:132
Takagi, Atsuhiko, 39:132
Takai, Ichiro, 39:137
Tanaka, Satoshi, 39:936
Tate, Robert A., 39:62
Teehan, Brendan P., 39:8
Teoh, S. H., 39:929
Teschan, Paul E., 39:957
Tessmer, John, 39:942
Thyagarajan, Kalathi, 39:106
Tobe, Takayoshi, 39:93
Tokars, Jerome I., 39:71, 39:966
Tokunaga, Kouichi, 39:126
Tominaga, Ryuji, 39:126
Tu, Roger, 39:106
Turina, M., 39:43
Twardowski, Zbylut J., 39:904
Tzamaloukas, Antonios H., 39:880

U

Uden, Donald L., 39:39, 39:942

V

Verrier, Edward D., 39:918
von Recum, Andreas F., 39:10
von Segesser, L. K., 39:43
Voynikov, Tencho, 39:141

W

Wang, Jia-Yi, 39:946
Wickham, Emily, 39:106
Wilson, Gregory J., 39:114
Wolfson, Marsha, 39:864

Y

Yamamoto, Kyoko, 39:132
Yamanishi, Yasuko, 39:141
Yano, Mitsuhiro, 39:120
Yasui, Hisataka, 39:126
Yokote, Yuji, 39:103

Z

Zager, Philip G., 39:880
Zwischenberger, Joseph B., 39:97


STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970: Section 3685. Title 39 United States Code) Date of Filing—October 1, 1993; Title of Publication—ASAIO Journal; Publication No.—08897190; Frequency of Issue—Quarterly; Annual Subscription Price—$170.00; Location of Known Office of Publication—12107 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of the Headquarters or General Business Offices of the Publisher—J. B. Lippincott Company, 227 East Washington Square, Philadelphia, PA 19106; Publisher—American Society for Artificial Internal Organs, Inc., P.O. Box C, Boca Raton, FL 33429-0468; Editor—Eli A. Friedman, MD, Box 52, Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203; Managing Editor—Todd Hummel, 227 East Washington Square, Philadelphia, PA 19106; Owner—American Society for Artificial Internal Organs, Inc., PO Box C, Boca Raton, FL 33429-0468; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—None. A. Total no. copies printed (*net press run*), average 3300, actual 3200; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 2403, actual 2543; C. Total paid circulation, average 2403, actual 2543; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 56, actual 43; E. Total distribution (*sum of C and D*), average 2459, actual 2586; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 841, actual 614; 2. Returns from news agents, none; G. Total (*sum of E and F—should equal net press runs shown in A*), average 3300, actual 3200. I certify that the statements made by me above are correct and complete. Virginia B. Martin, *Vice President.*